Published in J Thorac Dis on December 01, 2010
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Alveolar type II cells possess the capability of initiating lung tumor development. PLoS One (2012) 0.96
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis. Transl Lung Cancer Res (2015) 0.88
Mycobacterium bovis BCG promotes tumor cell survival from tumor necrosis factor-α-induced apoptosis. Mol Cancer (2014) 0.81
The role of natural killer cells in pulmonary immunosurveillance. Front Biosci (Schol Ed) (2013) 0.81
Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn) (2014) 0.80
The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer. Chin J Cancer Res (2012) 0.78
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med (2003) 10.40
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol (2006) 7.87
Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med (2001) 5.76
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
The emerging role of CTLA-4 as an immune attenuator. Immunity (1997) 5.35
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27
Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab (2003) 5.27
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity (1999) 3.84
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79
Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem (1990) 3.70
Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse. Nature (1959) 3.67
Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics (1994) 2.93
Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol (2008) 2.90
T cell defined tumor antigens. Curr Opin Immunol (1997) 2.90
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol (2002) 2.54
Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41
Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene (2003) 2.30
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol (2005) 2.25
Immune regulation of cancer. J Clin Oncol (2010) 1.99
Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res (1987) 1.99
Overview of interleukin-2 function, production and clinical applications. Cytokine (2004) 1.86
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol (1994) 1.83
How tumours escape mass destruction. Oncogene (2008) 1.82
Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice. Nat Genet (2006) 1.77
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61
GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine (2007) 1.58
MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer (2009) 1.53
A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl (1953) 1.51
Postoperative empyema improves survival in lung cancer. Documentation and analysis of a natural experiment. N Engl J Med (1972) 1.47
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev (2010) 1.43
Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther (2006) 1.43
Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. Eur J Cancer (2007) 1.40
Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol (2007) 1.36
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med (2001) 1.29
Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells. J Immunol (2008) 1.27
Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res (1992) 1.19
A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res (2000) 1.12
Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol (2008) 1.08
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res (1999) 1.08
Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma (2008) 0.95
Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg (1981) 0.93
Cancers after renal transplantation. Transplant Rev (Orlando) (2008) 0.92
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res (1996) 0.91
Anti-idiotype antibodies in cancer treatment. Oncogene (2007) 0.90
Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother (2002) 0.88
Cutting edge: MHC class II expression by pulmonary nonhematopoietic cells plays a critical role in controlling local inflammatory responses. J Immunol (2010) 0.88
Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia (2010) 0.87
Annual review of advances in lung cancer clinical research: a report for the year 2009. J Thorac Oncol (2010) 0.85
Five-year results of a controlled study of BCG immunotherapy after surgical resection in bronchogenic carcinoma. Thorax (1982) 0.84
Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol (2008) 0.84
Intratumoral Bacillus Calmette-Guérin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial. Cancer Res (1986) 0.84
Antibodies designed as effective cancer vaccines. MAbs (2010) 0.81
Vaccination strategies in follicular lymphoma. Curr Hematol Malig Rep (2009) 0.81
Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother (1986) 0.78
Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer (1995) 0.78
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res (1999) 0.77
Comparison of lung tumorigenesis induced by urethan in athymic nude mice and euthymic littermates. Jikken Dobutsu (1994) 0.77
Gangliosides and neutral glycosphingolipids of normal tissue and oat cell carcinoma of human lung. Biochim Biophys Acta (1986) 0.76
Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma. Dermatology (1992) 0.76
Possible immune factors in spontaneous regression of bronchogenic carcinoma. Ten year survival in a patient treated with minimal (1,200 r) radiation alone. Am J Surg (1970) 0.76
Specific and nonspecific immunotherapy as an adjunct to curative surgery for cancer of the lung. Yale J Biol Med (1982) 0.76
Vitiligo-like lesions following immunotherapy with IFN alpha and IL-2 in melanoma patients. Eur J Cancer (1994) 0.76
A prevalence of posttransplantation cancers compared with cancers in people with human immunodeficiency virus/acquired immunodeficiency syndrome after highly active antiretroviral therapy. Transplant Proc (2008) 0.75
Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 7.10
In vivo two-photon imaging reveals monocyte-dependent neutrophil extravasation during pulmonary inflammation. Proc Natl Acad Sci U S A (2010) 2.54
Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg (2010) 2.06
PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest (2006) 1.93
Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med (2002) 1.84
B lymphocytes from early vertebrates have potent phagocytic and microbicidal abilities. Nat Immunol (2006) 1.81
Cutting edge: Acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol (2009) 1.64
Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells. J Immunol (2005) 1.61
Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice. J Clin Invest (2013) 1.57
Sternoclavicular joint infection: a comparison of two surgical approaches. Ann Thorac Surg (2011) 1.52
Parasympathetic stimulation via the vagus nerve prevents systemic organ dysfunction by abrogating gut injury and lymph toxicity in trauma and hemorrhagic shock. Shock (2013) 1.51
T cell expression of MyD88 is required for resistance to Toxoplasma gondii. Proc Natl Acad Sci U S A (2008) 1.43
Nonoperative management of large tracheal injuries. J Thorac Cardiovasc Surg (2008) 1.40
Maintenance of airway epithelium in acutely rejected orthotopic vascularized mouse lung transplants. Am J Respir Cell Mol Biol (2007) 1.33
Orthotopic mouse lung transplantation as experimental methodology to study transplant and tumor biology. Nat Protoc (2009) 1.30
Lymph node evaluation in video-assisted thoracoscopic lobectomy versus lobectomy by thoracotomy. Ann Thorac Surg (2010) 1.29
Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis. J Clin Invest (2010) 1.29
CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells. Immunol Lett (2007) 1.29
Intravital 2-photon imaging of leukocyte trafficking in beating heart. J Clin Invest (2012) 1.28
Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology (2002) 1.23
Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg (2010) 1.15
CD4+ T lymphocytes are not necessary for the acute rejection of vascularized mouse lung transplants. J Immunol (2008) 1.14
Outcomes and perception of lung surgery with implementation of a patient video education module: a prospective cohort study. J Am Coll Surg (2012) 1.13
Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance. Blood (2011) 1.12
Endoscopic ultrasound for early stage esophageal adenocarcinoma: implications for staging and survival. Ann Thorac Surg (2011) 1.12
Vascular endothelium does not activate CD4+ direct allorecognition in graft rejection. J Immunol (2004) 1.10
National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancer. J Thorac Oncol (2014) 1.05
Processes of sterile inflammation. J Immunol (2013) 1.04
A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis. J Thorac Cardiovasc Surg (2011) 1.03
Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Invest (2014) 0.99
Treatment of malignant pleural effusion: a cost-effectiveness analysis. Ann Thorac Surg (2012) 0.99
HIF-1α signaling by airway epithelial cell K-α1-tubulin: role in fibrosis and chronic rejection of human lung allografts. Cell Immunol (2011) 0.97
Mouse vascular endothelium activates CD8+ T lymphocytes in a B7-dependent fashion. J Immunol (2002) 0.97
Recurrent empyema secondary to persistent spinal compression of the left main bronchus. J Thorac Cardiovasc Surg (2012) 0.96
Cutting edge: Pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating B7 expression on neutrophils. J Immunol (2012) 0.96
Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am J Respir Crit Care Med (2014) 0.94
Orthotopic vascularized right lung transplantation in the mouse. J Thorac Cardiovasc Surg (2010) 0.93
Completion pneumonectomy: outcomes for benign and malignant indications. Ann Thorac Surg (2013) 0.93
In vivo imaging implicates CCR2(+) monocytes as regulators of neutrophil recruitment during arthritis. Cell Immunol (2012) 0.93
Strain-specific variation in murine natural killer gene complex contributes to differences in immunosurveillance for urethane-induced lung cancer. Cancer Res (2012) 0.92
Pattern of ischemia reperfusion injury in a mouse orthotopic liver transplant model. J Surg Res (2004) 0.92
Five-year update on the mouse model of orthotopic lung transplantation: Scientific uses, tricks of the trade, and tips for success. J Thorac Dis (2012) 0.91
Tumor location is not an independent prognostic factor in early stage non-small cell lung cancer. Ann Thorac Surg (2010) 0.90
Dexamethasone inhibits early regenerative response of rat liver after cold preservation and transplantation. Hepatology (2003) 0.89
Oxidative modification of the intestinal mucus layer is a critical but unrecognized component of trauma hemorrhagic shock-induced gut barrier failure. Am J Physiol Gastrointest Liver Physiol (2012) 0.89
Mechanism of T cell-mediated endothelial apoptosis. Transplantation (2002) 0.89
The role of passenger leukocyte genotype in rejection and acceptance of rat liver allografts. Transplantation (2002) 0.88
Cutting edge: MHC class II expression by pulmonary nonhematopoietic cells plays a critical role in controlling local inflammatory responses. J Immunol (2010) 0.88
Lung transplantation and donation after cardiac death: a single center experience. Ann Thorac Surg (2009) 0.88
Attaining proficiency with endobronchial ultrasound-guided transbronchial needle aspiration. J Thorac Cardiovasc Surg (2013) 0.88
Quantitative monitoring of mouse lung tumors by magnetic resonance imaging. Nat Protoc (2012) 0.87
Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation (2002) 0.87
The intestinal mucus layer is a critical component of the gut barrier that is damaged during acute pancreatitis. Shock (2014) 0.86
Intraluminal nonbacterial intestinal components control gut and lung injury after trauma hemorrhagic shock. Ann Surg (2014) 0.86
Inflammatory triggers of acute rejection of organ allografts. Immunol Rev (2014) 0.86
Tuberculosis presenting as an endobronchial mass. J Thorac Cardiovasc Surg (2007) 0.85
Treatment Outcomes in Stage I Lung Cancer: A Comparison of Surgery and Stereotactic Body Radiation Therapy. J Thorac Oncol (2015) 0.84
CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation (2002) 0.84
Strain-specific susceptibility for pulmonary metastasis of sarcoma 180 cells in inbred mice. Cancer Res (2010) 0.84
Massive bilateral chylothoraces complicating mediastinal granulomatous disease. Ann Thorac Surg (2009) 0.83
Apyrase treatment prevents ischemia-reperfusion injury in rat lung isografts. J Thorac Cardiovasc Surg (2009) 0.83
Quantitative analysis of tumor burden in mouse lung via MRI. Magn Reson Med (2011) 0.83